ZYCEVA 150 MG

Across the clinical settings represented in this database, Erlotinib is associated with EGFR-mutated NSCLC; pancreatic cancer in selected combination therapy. Its pharmacology is summarized by the fact that it reversibly inhibits EGFR tyrosine kinase and downstream signaling. EGFR pathway dependence is the key treatment concept, so molecular characterization of the tumor is closely tied to appropriate use. The medicine is classified as Targeted Therapy; EGFR Tyrosine Kinase Inhibitor and belongs to the EGFR TKI group. The associated tumor types are NSCLC; Pancreatic Cancer, while the documented regimen examples are Erlotinib monotherapy; selected pancreatic cancer combination with gemcitabine. These details place the agent within specific treatment pathways rather than describing a generalized use across oncology. Molecular and disease-specific eligibility can therefore be more important than tumor location alone when the treatment is considered. Any selection criterion explicitly included in the indication—whether molecular, receptor-based, disease-stage related, or dependent on prior therapy—should be retained when interpreting the record. Related agents may have overlapping indications but still differ in target or clinical positioning. This description is intended for professional reference and avoids individualized prescribing recommendations. Current labels and disease-specific guidelines should be consulted because accepted uses can change with new evidence and regulatory updates.